|1.||Lupu, Mihaela: 1 article (08/2006)|
|2.||Higgins, Brian: 1 article (08/2006)|
|3.||Packman, Kathryn: 1 article (08/2006)|
|4.||Koutcher, Jason A: 1 article (08/2006)|
|5.||Muruganandham, Manickam: 1 article (08/2006)|
|6.||Dyke, Jonathan P: 1 article (08/2006)|
|7.||Kolinsky, Kenneth: 1 article (08/2006)|
|8.||Linn, Michael: 1 article (08/2006)|
|9.||Matei, Cornelia: 1 article (08/2006)|
08/01/2006 - "Treatment with RO0281501 resulted in significant growth retardation of H460a tumors. "
08/01/2006 - "Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T."
08/01/2006 - "The purpose of this study was to evaluate the vascular response of human lung tumor xenografts in vivo to RO0281501, an inhibitor of tyrosine kinase receptors, including vascular endothelial growth factor receptor 2, fibroblast growth factor receptor, and platelet-derived growth factor receptor, using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). "
|1.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|2.||Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)
|3.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|4.||Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)
|1.||Heterologous Transplantation (Xenotransplantation)